Evaluation of neutralizing antibodies produced by papaya mosaic virus nanoparticles fused to the E2EP3 peptide epitope of Chikungunya envelope.

Hussin A. Rothan¹ and Rohana Yusof²

¹Department of Biology, College of Arts and Sciences, Georgia State University, Atlanta, GA, USA

²Department of Molecular Medicine, Faculty of Medicine, University of Malaya, 50603, Kuala Lumpur, Malaysia

Correspondence: hrothan@gsu.edu

1 **Abstract**

2 Chikungunya virus (CHIKV) infection is the cause of acute symptoms and chronic symmetrical
3 polyarthrititis associated with long-term morbidity and mortality. Currently, there is no available
4 licensed vaccine or particularly useful drug for human use against CHIKV infection. This study was
5 conducted to evaluate the efficacy of antibodies produced by papaya mosaic virus (PapMV)
6 nanoparticles fused to E2EP3 peptide of CHIKV envelope as a recombinant CHIKV vaccine. PapMV,
7 PapMV E2EP3, and E2EP3 PapMV were produced in *E. coli* with an approximate size of 27 to 30
8 kDa. ICR mice (5 to 6 weeks of age) were injected subcutaneously with 25 micrograms of vaccine
9 construct, and ELISA measured the titer of CHIKV specific IgG antibodies. The results showed that
10 both recombinant proteins E2EP3 PapMV and PapMV E2EP3 were able to induce IgG antibodies
11 production in immunized mice against CHIKV while immunization with recombinant PapMV showed
12 no IgG antibodies induction. The neutralizing activity of the antibodies generated by either E2EP3
13 PapMV or PapMV E2EP3 exhibited similar inhibition to CHIKV replication in Vero cells using the
14 cells based antibody neutralizing assay and analyzed by plaque formation assay. This study showed
15 the effectiveness of nanoparticles vaccine generated by fusing epitope peptide of CHIKV envelope to
16 papaya mosaic virus envelope in inducing a robust immune response in mice against CHIKV. The
17 data showed that levels of neutralizing antibodies correlate with a protective immune response
18 CHIKV replication.

19 **Keywords:** Chikungunya virus, vaccine, papaya mosaic virus, nanoparticles.

20

21

22

23

24

25

26

27

1 **Introduction**

2 Chikungunya virus (CHIKV) is a mosquito-borne enveloped alphavirus belong to the family of
 3 *Togaviridae*. CHIKV contains a single-stranded positive-sense RNA genome of approximately 11.8
 4 kbp, which is capped and polyadenylated, encoding two open reading frames (ORFs)[1]. The 5' ORF
 5 is expressed via cap-dependent translation as an ns-P1-3 or ns-P1-4 polyprotein, and it is cleaved by
 6 an nsP2 encoded protease. The structural protein ORF is translated into three main structural proteins:
 7 the capsid (C), the envelope glycoproteins E2 and E1, and two other proteins of E3 and 6K[2]. The
 8 envelop polyprotein of E3E26KE1 is then processed in the endoplasmic reticulum. The mature virion
 9 contains 240 of E2/E1 heterodimers arranged in 80 trimeric spikes on the surface, which are inserted
 10 into the plasma membrane of infected cells after transport through the secretory pathway. The E2
 11 trimeric spikes are essential for budding of new virus particles and host receptor recognition and
 12 attachment, while E1 is responsible for cell entry via pH-dependent endocytosis. The capsid protein is
 13 cleaved from the structural polyprotein and encapsidates the cytoplasmic viral genomic RNA.
 14 Cytoplasmic nucleocapsids containing the genomic RNA and 240 copies of the capsid protein bud
 15 from the cells surface to acquire the virion envelope and envelope protein spikes[3,4].

16 At present, there is no available licensed vaccine or particularly useful drug for human use for any
 17 *alphavirus*. Several pre-clinical CHIKV vaccines were described. Inactivated virus formulation, like a
 18 formalin-inactivated *alphavirus* vaccine, has proved to be immunogenic in humans [5,6]. Live-
 19 attenuated CHIKV vaccines are found to be immunogenic, but they have side effects like arthralgia in
 20 a human phase II study[7,8]. Antibodies are required for protection against CHIKV infections, but
 21 DNA vaccines have not been able to generate antibody responses in humans[6,9] effectively.
 22 Chimeric virus vaccines, recombinant adenovirus vaccines, subunit protein vaccines are other
 23 examples of CHIKV vaccines[10,11]. In this study, an 18-amino acid peptide derived from CHIKV
 24 envelop was fused to the Papaya Mosaic virus envelop (PapMV) as a platform for creating vaccine
 25 nanoparticles. The recombinant vaccine was able to induce an immune response in mice against
 26 CHIKV. The data showed that levels of neutralizing antibodies correlate with a protective immune
 27 response, which can accelerate the development accessibility of CHIKV.

1 **Methods**

2 *1. Virus and cells*

3 A clinical isolate of CHIKV recovered from the serum of infected patients (CHIKV isolate,
4 SGEHICHS277108, Accession FJ445510) was used for propagation by a single passage in C6/36
5 mosquito cells. Vero cells (ATCC CCL-81) were obtained from the American Type Culture
6 Collection (ATCC; Rockville, MD, USA) and cultured in complete Dulbecco's modified Eagle's
7 medium (DMEM) supplemented with 10% fetal bovine serum (FBS) as growth medium or 2% FBS
8 as maintenance medium.

9 *2. Cloning and expression of CHIKV nanoparticles vaccine*

10 Recombinant Papaya virus particles fused with CHIKV peptide epitope E2EP3. Recombinant plasmid
11 construction was carried out as previously described[12-14]. In brief, protein sequences of PapMV,
12 PapMV-E2EP3, and E2EP3- PapMV were converted to DNA sequences and optimized based on *E.*
13 *coli* preferred codons. Oligonucleotides of 60 mer were designed with an overlapping 3' ends (15
14 nucleotides) using the Primer3 (version 0.4.0) analysis software. The long oligonucleotides were
15 annealed, and the mixture of the complementary overlapping oligonucleotides was extended and
16 filled-in with dNTP and Klenow DNA polymerase (Invitrogen, USA). The full DNA fragment was
17 cloned downstream of T7 promoter of the *E. coli* expression vector. The recombinant plasmid DNA
18 was transformed into *E. coli* BL21, followed by screening and restriction digestion. The recombinant
19 plasmids were isolated, and the purified plasmids were sequenced to verify the correct sequences
20 without mutations. *E. coli* harboring recombinant vectors were cultured in 1 L of LB broth medium
21 supplemented with ampicillin and incubated at 37°C. The bacterial cells were harvested, lysed, and
22 sonicated on the ice after the induction of protein expression by IPTG. Recombinant protein in the
23 supernatant was purified to 90% purity by a single-step chromatography on Ni⁺⁺ - metal chelate
24 affinity (Qiagen, UK) columns and eluting at 0.5 M imidazole. The eluted protein profile was
25 analyzed using SDS- PAGE, and the peak fractions were pooled[12,15]. The purified proteins were
26 concentrated via Vivaspin® 20 concentrator tubes (Viva products, Littleton, MA, USA).

27 *3. Immunization*

28

In vivo experiments were carried out following the University of Malaya guidelines on the Care and Use of Laboratory Animals following approval of the animal ethics protocols used in the investigation by the Animal Ethics Committee of the University of Malaya. Twelve ICR mice (5–6 weeks of age) were injected subcutaneously with 25 µg of PapMV, E2EP3-PapMV, and PapMV-E2EP3 or endotoxin-free PBS (each group 3 mice). Primary immunization was followed by one booster dose given two weeks later. Sera samples were collected after 21 days after the first injection and stored at –20 °C until analysis.

4. Determination of the CHIKV-specific IgG antibodies

The titer of CHIKV-specific IgG antibodies was performed by ELISA, as previously described[16]. In brief, 96-well plates were coated with purified CHIKV antigen in PBS for overnight, blocked with blocking buffer (PBS containing 0.05% Tween 20 and 5% ABS) and incubated for two h at room temperature. Plasma samples were then diluted at 1:100 to 1:10,000 in blocking buffer and incubated for two h at room temperature. HRP-conjugated goat anti-mouse IgG was used to detect mouse antibodies bound to virus-coated wells. Reaction mixtures were developed using TMB (3,3,5,5-tetramethylbenzidine) substrate (Sigma-Aldrich), and the absorbance was measured at 450 nm.

5. *In vitro* neutralization

Neutralizing activity of antibodies was tested in triplicate and analyzed by plaque formation assay in Vero cells. CHIKV was mixed at a multiplicity of infection (MOI) of 5, with either heat-inactivated mice serum (between 1:50 and 1:10,000) and incubated for 2 h at 37°C, with gentle agitation. Virus-antibody mixtures were then added to Vero cells seeded into 6-well plates and incubated for 2 h at 37°C with gentle shaking every 15 min. The medium was removed, and cells were washed with PBS and a new DMEM medium supplied with 2% FBS and incubated for 72 h at 37°C. Culture supernatant was collected, and virus titers were determined by plaque formation assay.

6. Plaque formation assay

This assay was carried out as previously described[17-19]. In brief, A 10-fold serial dilution of culture supernatant of CHIKV infected cells was added to fresh Vero cells grown in 6-well plates (0.5×10^6 cells) and incubated for 1 h at 37°C. The cells were overlaid with DMEM (maintenance medium) containing 0.5% agarose. Viral plaques were stained with crystal violet dye after 5-day of incubation.

Virus titers were calculated according to the following formula: Titer (p.f.u./ml) = number of plaques/volume of the diluted virus added to the well $\times$ dilution factor of the virus used to infect the well in which the plaques were enumerated.

7. Statistical analysis

All the assays were performed in quadruplicate, and the statistical analyses were performed using GraphPad Prism version 5.01 (GraphPad Software, San Diego, CA). P values <0.05 were considered significant. The error bars are expressed as $\pm$ SD.

Results and Discussion

CHIKV disease is characterized by acute symptoms that generally last about a week and are self-limiting and chronic symmetrical polyarthritis/polyarthralgia lasting for months to years, indicating long-term morbidity and mortality of CHIKV[20-22]. In recent years, CHIKV disease has become a global public health problem. However, there is no licensed vaccine available for CHIKV. The current study provides a method of producing recombinant CHIKV vaccine nanoparticles.

1. Production of the recombinant vaccine nanoparticles

In this study, an 18-amino acid peptide (E2EP3₂₈₀₀₋₂₈₁₈) derived from CHIKV envelope was fused to the Papaya Mosaic virus envelop (PapMV) as a platform for creating vaccine nanoparticles. Five residues extension from N- and C- termini of E2EP3 peptide were included for favor natural processing of the peptide. The position of E2EP3 peptide might influence the formation and immunogenicity of the nanoparticles. Thus, the peptide was fused to either N- or C- termini of PapMV (Fig. 1A). To achieve this aim, three recombinant plasmid constructs were generated to express the Papaya Mosaic virus envelop without insertion (*PapMV*), with insertion at the N- terminus (*E2EP3-PapMV*) and with insertion at C- terminus (*PapMV-E2EP3*) as presented in Figure 1A. The recombinant plasmids were transformed into *E. coli* to express three recombinant proteins named PapMV, E2EP3 -PapMV, and PapMV- E2EP3[23]. The recombinant proteins were affinity purified on a Ni⁺⁺-column via 6XHis tag. The expected size of these proteins was approximately 27 to 30 kD. (Fig. 1B). The concentrated recombinant proteins were visualized under transmission electron microscopy. The results obtained by transmission electron microscopy showed there are two

structures of nanoparticles, typical long rod-shaped (approximately 120 nm in length) and disc-shaped structure (approximately 25 nm diameter) for PapMV, E2EP3 -PapMV and PapMV- E2EP3 (Fig. 1C).

2. *The recombinant nanoparticles induced an immune response in mice*

In this study, the immune response to PapMV nanoparticles was examined by a subcutaneous injection of twelve mice with 25 µg each of the recombinant PapMV, E2EP3 -PapMV, PapMV- E2EP3 or endotoxin-free PBS. A booster dose was given on day 15 after primary immunization. Mice sera were assayed for anti- PapMV, E2EP3-PapMV, and PapMV-E2EP3 antibodies. The results showed both recombinant proteins E2EP3-PapMV and PapMV-E2EP3 were able to induce IgG antibodies production in immunized mice against CHIKV while immunization with recombinant PapMV or endotoxin-free PBS showed no IgG antibodies induction (Fig. 2). Our data are supported by recent studies that show that protective antibodies play a role in the control of CHIKV infection. Previous studies show that the neutralization of viruses by anti-CHIKV antibodies protects against CHIK infection[4,24]. Natural CHIKV infections induce high neutralizing antibody levels from 40 to 20,000 in titer[25], which have been detected in CHIKV patients during the infection course. The presence of IgG antibodies correlates with viral clearance and long-term protection[26].

3. *The sera of immunized mice inhibited virus infection in vitro*

One of the advantages of peptidic vaccination is the good mimicry of the fused epitope. To check if the peptide derived from the CHIKV surface glycoprotein that is fused to the C-terminal or N-terminal of the PapMV can exhibit differences antibodies affinity to CHIKV. The neutralizing activity of antibodies generated by either E2EP3-PapMV or PapMV-E2EP3 was tested in vitro using the cells-based antibody neutralizing assay and analyzed by plaque formation assay. CHIKV was mixed at a multiplicity of infection (MOI) of 5, with either heat-inactivated mice serum using increasing dilution factor. The results showed that E2EP3-PapMV and PapMV-E2EP3 exhibited similar inhibition to CHIKV replication in Vero cells (Fig. 3A and 3B). Dilutions at 1:50 to 1:200 of mice sera containing anti-CHIKV antibodies were able to neutralize more than 80% of CHIKV replication compare to the higher dilution factors.

1 It has been known that Virus-like particle (VLP) formulation mimics the native virus surface
 2 architecture and protein conformation, and it induces protective antibody responses in the absence of
 3 adjuvant [27]. A recent CHIKV VLP-based vaccine provides protection in both mice and non-human
 4 primates by DNA transfection of mammalian cells, but this system out-performs cost and
 5 scalability[28-30], therefore, the CHIKV VLPs in the presence of adjuvant are economical and easy to
 6 scale up for an epidemic response. It has been shown that the E2 domain of the CHIKV envelope
 7 glycoprotein, which binds with high affinity to CHIKV, is responsible for virus neutralization. This
 8 data shows that levels of neutralizing antibodies correlate with a protective immune response, which
 9 can accelerate the development accessibility of the CHIKV vaccine[4]. Based on the advantage of
 10 nanoparticle vaccine, we sought to test the protection efficiency, and immunogenicity of engineered
 11 papaya mosaic virus nanoparticles (PapMV-VLPs) fused with peptide-epitope derived from
 12 Chikungunya E2 glycoprotein to trigger a protective immune response against CHIKV. The PapMV
 13 platform is rod-shaped (15nm in diameter~150-250nm in length, which was recently shown to induce
 14 a high antibody response against a hepatitis C virus (HCV) epitope[31,32].

15 In conclusion, vaccination is the most cost-effective means of protecting the at-risk populations in
 16 CHIK-endemic developing countries. CHIK epidemics are, however, explosive and rapidly moving,
 17 but not predictable. This study showed the effectiveness of nanoparticles vaccine generated by fusing
 18 epitope peptide of CHIKV envelope to papaya mosaic virus envelop (PapMV). The recombinant
 19 vaccine was able to induce an immune response in mice against CHIKV. The data showed that levels
 20 of neutralizing antibodies correlate with a protective immune response, which can accelerate the
 21 development accessibility of CHIKV.

22 **Ethical approval:** Animal experiment was carried out following the University of Malaya guidelines
 23 on the Care and Use of Laboratory Animals following approval of the animal ethics protocols used in
 24 the investigation by the Animal Ethics Committee of the University of Malaya.

25

26

References:

1. Khan AH, Morita K, Parquet Md Mdel C, Hasebe F, Mathenge EG, et al. (2002) Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. *J Gen Virol* 83: 3075-3084.
2. Schmaljohn AL, McClain D (1996) Alphaviruses (Togaviridae) and Flaviviruses (Flaviviridae). In: th, Baron S, editors. *Medical Microbiology*. Galveston (TX).
3. Li L, Jose J, Xiang Y, Kuhn RJ, Rossmann MG (2010) Structural changes of envelope proteins during alphavirus fusion. *Nature* 468: 705-708.
4. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT (2012) Chikungunya virus and prospects for a vaccine. *Expert Rev Vaccines* 11: 1087-1101.
5. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, et al. (2009) Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. *Vaccine* 27: 2513-2522.
6. Gardner J, Anraku I, Le TT, Larcher T, Major L, et al. (2010) Chikungunya virus arthritis in adult wild-type mice. *J Virol* 84: 8021-8032.
7. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, et al. (2011) Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. *PLoS Pathog* 7: e1002142.
8. Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, et al. (2012) Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. *Vaccine* 30: 4638-4643.
9. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, et al. (2011) A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. *PLoS Negl Trop Dis* 5: e928.
10. Gao S, Song S, Zhang L (2019) Recent Progress in Vaccine Development Against Chikungunya Virus. *Front Microbiol* 10: 2881.
11. Rezza G, Weaver SC (2019) Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development. *PLoS Negl Trop Dis* 13: e0006919.
12. Rothan HA, Bahrani H, Mohamed Z, Abd Rahman N, Yusof R (2014) Fusion of protegrin-1 and plectasin to MAP30 shows significant inhibition activity against dengue virus replication. *PLoS One* 9: e94561.
13. Rothan HA, Bahrani H, Shankar EM, Rahman NA, Yusof R (2014) Inhibitory effects of a peptide-fusion protein (Latarcin-PAP1-Thanatin) against chikungunya virus. *Antiviral Res* 108: 173-180.
14. Rothan HA, Mohamed Z, Suhaeb AM, Rahman NA, Yusof R (2013) Antiviral cationic peptides as a strategy for innovation in global health therapeutics for dengue virus: high yield production of the biologically active recombinant plectasin peptide. *OMICS* 17: 560-567.
15. Rothan HA, Ambikabothry J, Abdulrahman AY, Bahrani H, Golpich M, et al. (2015) Scalable Production of Recombinant Membrane Active Peptides and Its Potential as a Complementary Adjunct to Conventional Chemotherapeutics. *PLoS One* 10: e0139248.
16. Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, et al. (2011) A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. *Vaccine* 29: 2803-2809.
17. Rothan HA, Bahrani H, Mohamed Z, Teoh TC, Shankar EM, et al. (2015) A combination of doxycycline and ribavirin alleviated chikungunya infection. *PLoS One* 10: e0126360.
18. Rothan HA, Mohamed Z, Paydar M, Rahman NA, Yusof R (2014) Inhibitory effect of doxycycline against dengue virus replication in vitro. *Arch Virol* 159: 711-718.
19. Rothan HA, Bahrani H, Rahman NA, Yusof R (2014) Identification of natural antimicrobial agents to treat dengue infection: In vitro analysis of latarcin peptide activity against dengue virus. *BMC Microbiol* 14: 140.

20. Goupil BA, Mores CN (2016) A Review of Chikungunya Virus-induced Arthralgia: Clinical Manifestations, Therapeutics, and Pathogenesis. *Open Rheumatol J* 10: 129-140.
21. Gasque P, Bandjee MC, Reyes MM, Viasus D (2016) Chikungunya Pathogenesis: From the Clinics to the Bench. *J Infect Dis* 214: S446-S448.
22. Rothan HA, Bahrani H, Abdulrahman AY, Mohamed Z, Teoh TC, et al. (2016) Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo. *Antiviral Res* 127: 50-56.
23. Rothan HA, Suhaeb AM, Kamarul T (2013) Recombinant human adiponectin as a potential protein for treating diabetic tendinopathy promotes tenocyte progenitor cells proliferation and tenogenic differentiation in vitro. *Int J Med Sci* 10: 1899-1906.
24. Salazar-Gonzalez JA, Angulo C, Rosales-Mendoza S (2015) Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines. *Vaccine* 33: 3650-3658.
25. Lanciotti RS, Kosoy OL, Laven JJ, Panella AJ, Velez JO, et al. (2007) Chikungunya virus in US travelers returning from India, 2006. *Emerg Infect Dis* 13: 764-767.
26. Kam YW, Simarmata D, Chow A, Her Z, Teng TS, et al. (2012) Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. *J Infect Dis* 205: 1147-1154.
27. Metz SW, Pijlman GP (2011) Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system. *J Invertebr Pathol* 107 Suppl: S16-30.
28. Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, et al. (2009) Prophylaxis and therapy for Chikungunya virus infection. *J Infect Dis* 200: 516-523.
29. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, et al. (2010) A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. *Nat Med* 16: 334-338.
30. Roldao A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM (2010) Virus-like particles in vaccine development. *Expert Rev Vaccines* 9: 1149-1176.
31. Tremblay MH, Majeau N, Gagne ME, Lecours K, Morin H, et al. (2006) Effect of mutations K97A and E128A on RNA binding and self assembly of papaya mosaic potexvirus coat protein. *FEBS J* 273: 14-25.
32. Denis J, Majeau N, Acosta-Ramirez E, Savard C, Bedard MC, et al. (2007) Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: evidence for the critical function of multimerization. *Virology* 363: 59-68.

Figures legends

Figure 1. Design and expression of recombinant CHIKV vaccine nanoparticles. (A) The amino acid sequence of E2EP3 peptide derived from CHIKV envelop was fused to the Papaya Mosaic virus envelop (PapMV) as a platform for creating vaccine nanoparticles. The peptide sequence (bold) was flanked from N- and C- termini with five residues extension from CHIKV envelop (italic-underlined) for favor natural processing of the peptide. The peptide was fused either at N- or C- terminus resulting in two recombinant proteins PapMV, E2EP3 -PapMV and PapMV- E2EP3 or without insertion PapMV. (B) The recombinant proteins were affinity purified on a Ni⁺⁺-column via 6XHis tag. The expected size of these proteins was approximately 27 to 30 kD based on SDS-page results, M (marker), L1 (PapMV), L2 (E2EP3 -PapMV) and L3 (PapMV- E2EP3). (C) The transmission electron microscopy showed there are two structures of nanoparticles, a disc-shaped structure (approximately 25 nm diameter) and long rod-shaped (about 120 nm in length) for PapMV, E2EP3 -PapMV and PapMV- E2EP3.

Figure 2. Antibody profiles of PapMV nanoparticles in immunized mice. Virus-specific IgG antibody titers in each serum sample were determined by ELISA using purified CHIKV virions. Mice

were injected subcutaneously with 25 µg of PapMV, E2EP3-PapMV, and PapMV-E2EP3 or endotoxin-free PBS. Primary immunization was followed by one booster dose given 2 weeks later. Sera samples were collected 21 days post-injection and diluted at 1:100 to 1:10,000 in blocking buffer for ELISA assay. The recombinant proteins E2EP3-PapMV and PapMV-E2EP3 were able to induce IgG antibodies production in immunized mice against CHIKV while immunization with recombinant PapMV or endotoxin-free PBS showed no IgG antibodies induction.

Figure 3. Evaluation of neutralizing activity of mice sera containing antibodies against CHIKV replication in Vero cells. (A) CHIKV was mixed with heat-inactivated mice sera at serial dilutions ranged from 1:50 to 1:10,000. After incubation for 2 h at 37°C, virus-antibody mixtures were then added to Vero cells at an MOI of 5 and incubated for 72 h. Culture supernatant was collected and virus titers were determined by plaque formation assay. (B) A serial dilution of culture supernatant of CHIKV infected cells treated with 1:50 dilution was added to fresh Vero cells grown in 6-well plates. The cells were overlaid with DMEM and viral plaques were stained with crystal violet dye after 5-day of incubation.

Figure 1

Figure 2

1

2 Figure 3

(B)

3

4